First Tracks Biotherapeutics, Inc.(TRAX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TRAX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for First Tracks Biotherapeutics, Inc. (TRAX), a Healthcare sector company. TRAX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), First Tracks Biotherapeutics, Inc. reports net income of $-33.4M, free cash flow of $-31.9M. Top institutional holders of TRAX by reported 13-F value include EcoR1 Capital, TCG Crossover Management, FMR, based on the most recent SEC filings. TRAX trades on the Nasdaq exchange and files with the SEC under CIK 2091349. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for First Tracks Biotherapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-33.4M
Free Cash Flow
Q2 2026
$-31.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProTotal Assets
| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Total Assets | $330.5M | — |
Get alerted when TRAX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for First Tracks Biotherapeutics, Inc. including:
Top Institutional Holders of TRAX
EcoR1 Capital, LLC
$63.9M3,174,519 shTCG Crossover Management, LLC
$58.3M2,895,304 shFMR LLC
$41.3M2,054,127 shAffinity Asset Advisors, LLC
$40.9M2,032,012 shBlackRock, Inc.
$39.5M1,963,541 shTrails Edge Capital Partners, LP
$30.5M1,514,000 shVANGUARD CAPITAL MANAGEMENT LLC
$29.2M1,451,909 shJupiter Topco LLC
$22.0M1,091,464 shVestal Point Capital, LP
$20.4M1,013,000 shWoodline Partners LP
$18.5M917,176 sh
| Fund | Value | Shares |
|---|---|---|
| EcoR1 Capital, LLC | $63.9M | 3,174,519 |
| TCG Crossover Management, LLC | $58.3M | 2,895,304 |
| FMR LLC | $41.3M | 2,054,127 |
| Affinity Asset Advisors, LLC | $40.9M | 2,032,012 |
| BlackRock, Inc. | $39.5M | 1,963,541 |
| Trails Edge Capital Partners, LP | $30.5M | 1,514,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $29.2M | 1,451,909 |
| Jupiter Topco LLC | $22.0M | 1,091,464 |
| Vestal Point Capital, LP | $20.4M | 1,013,000 |
| Woodline Partners LP | $18.5M | 917,176 |
More Healthcare Companies
View all Healthcare →Put TRAX on your watchlist
Track score changes the day First Tracks Biotherapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TRAX a good stock to buy?
13F Pro's AI-powered analysis of First Tracks Biotherapeutics, Inc. (TRAX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TRAX are available on the TRAX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TRAX is classified as a small company.
Which hedge funds own TRAX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TRAX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of First Tracks Biotherapeutics, Inc.'s investment landscape.